Endocrine Therapy Does Not Increase Dementia Risk
Estrogen has been found to have beneficial effects on cognition. However, in women who have had hormone-receptor positive breast cancer (HR+BC), this hormone is usually blocked with endocrine therapy (ET) using either a selective estrogen receptor modulator or aromatase inhibitor. This has led to concern over possible detrimental effects of ET on cognitive function. Read more.

Repurposing Drugs for Breast Cancer
The expression “everything old is new again” doesn’t only apply to fashion and haircut trends, but it also applies to the use of medications. The term “drug repurposing” is sometimes used interchangeably with the terms “drug reprofiling,”’ “drug re-tasking,” “drug redesigning,” “drug resorting," "drug reindication," "indication switching," "therapeutic switching," or "drug repositioning." Read more.

Risk Factors With Hand-Foot Syndrome in Breast Cancer
Doxorubicin is often utilized in combination with cyclophosphamide, paclitaxel, or fluorouracil to treat breast cancer. However, a major limitation of doxorubicin therapy is cardiotoxicity. To mitigate this adverse effect, doxorubicin is available as a pegylated liposomal doxorubicin (PLD) formulation. While associated with fewer cardiac adverse cardiac effects, PLD is commonly associated with hand-foot syndrome. Read more.